Nuacht

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...
Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...
President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...
The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.
Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.
FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and ...
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...
A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany.